Skip to Content
Merck

Targeted Protein Degradation by Small Molecules.

Annual review of pharmacology and toxicology (2016-10-13)
Daniel P Bondeson, Craig M Crews
ABSTRACT

Protein homeostasis networks are highly regulated systems responsible for maintaining the health and productivity of cells. Whereas therapeutics have been developed to disrupt protein homeostasis, more recently identified techniques have been used to repurpose homeostatic networks to effect degradation of disease-relevant proteins. Here, we review recent advances in the use of small molecules to degrade proteins in a selective manner. First, we highlight all-small-molecule techniques with direct clinical application. Second, we describe techniques that may find broader acceptance in the biomedical research community that require little or no synthetic chemistry. In addition to serving as innovative research tools, these new approaches to control intracellular protein levels offer the potential to develop novel therapeutics targeting proteins that are not currently pharmaceutically vulnerable.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
C5 Lenalidomide-PEG5-NH2 hydrochloride
Sigma-Aldrich
(S,R,S)-AHPC-Me-C5-COOH, ≥95%
Sigma-Aldrich
Pomalidomide-2,6-diazaspiro[3.3]heptane, ≥95.0%
Sigma-Aldrich
Pomalidomide-piperazine-propanoic acid, ≥95.0%
Sigma-Aldrich
C5 Lenalidomide-piperazine-pyridine-alkyne-NH2 hydrochloride, ≥95%
Sigma-Aldrich
VH032-OH, ≥95%
Sigma-Aldrich
CCW16-C6-BocNH
Sigma-Aldrich
Pomalidomide-C5-phosphoramidite
Sigma-Aldrich
CCW16-PEG1-BocNH
Sigma-Aldrich
1-Piperazinecarboxylic acid, 4-(4-piperidinyl)-, 1,1-dimethylethyl ester, ≥98%
Sigma-Aldrich
4-(Aminoethyl)-1-N-Boc-piperidine, ≥95.0%
Sigma-Aldrich
FBnG-C3-PEG1-C3-NH2 hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-PEG2-C2-azide, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-CO-PEG4-C2-acid, ≥95%
Sigma-Aldrich
Thalidomide-O-amido-C8-NH2 trifluoroacetate, ≥95.0%
Sigma-Aldrich
Pomalidomide-piperidine-carboxylic acid, ≥95%
Sigma-Aldrich
Pomalidomide-PEG3-OH, ≥95%
Sigma-Aldrich
CCW16-C9-BocNH, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-CO-PEG1-C2-acid, ≥95%
Sigma-Aldrich
Pomalidomide-C9-NH2 hydrochloride
Sigma-Aldrich
3-Pyridinecarboxylic acid, 6-[4-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-1-piperazinyl]-, ≥95%
Sigma-Aldrich
Pomalidomide-piperazine, ≥ 95.0%
Sigma-Aldrich
VH 032 amide-alkyl C5-acid, ≥95%
Sigma-Aldrich
Pomalidomide-difluoroPEG1-C4-piperazine Hydrochloride, ≥95%
Sigma-Aldrich
FBnG-C3-PEG5-C3-NH2 hydrochloride, ≥95%
Sigma-Aldrich
4-Pentynoic acid, 5-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1-oxo-1H-isoindol-4-yl], ≥95.0%
Sigma-Aldrich
Pomalidomide-C2-NH2 hydrochloride, ≥95%
Sigma-Aldrich
Propanoic acid, 3-[2-[2-[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]amino]ethoxy]ethoxy]ethoxy]-, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-C9-NH2 hydrochloride, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-pentanoic-acid, ≥95%